Matthew Lepore is Pfizer's Corporate Secretary and Chief Counsel of the Corporate Governance Department. He heads the group responsible for working with institutional investors on a variety of governance issues to facilitate an open dialogue between the Company and its shareholders. Mr. Lepore works closely with the CEO and Chairman of the Board, General Counsel and other Senior Leadership on SEC and NYSE matters, emerging trends and practices in corporate governance, board related issues, global corporate financings/capital raising, M&A, pension fund and general corporate matters. In addition, a significant portion of Mr. Lepore's duties are spent working with the Board of Directors at and in preparation for Board meetings, as well as the meetings of several Board Committees. Mr. Lepore also has oversight of Shareholder Services, Pfizer's many subsidiaries, as well as Pfizer's Corporate Policies and Procedures. Mr. Lepore is responsible for Pfizer's Records and Information Management function, as well as the team providing legal support to Pfizer's DC office and nationwide lobbying efforts. Finally, as a member of the Legal Division's Executive Team and the Pfizer Legal Alliance (Pfizer's innovative outside counsel program) Steering Committee, he works broadly across the Division on various initiatives outside of the Governance Department.
Before coming to Pfizer, Mr. Lepore was a Partner with DLA Piper US LLP in Washington, DC, where he focused on risk management and product liability, providing legal and strategic analysis of client practices to minimize risks of investigation, regulations and litigation, for a variety of large corporations. He also has served as a Trial Attorney in the U.S. Department of Justice, representing the Executive Branch of Government in a variety of constitutional challenges to executive decision-making.
Mr. Lepore currently works with the Aspen Institute's Corporate Values Strategy Group, he is an Advisory Board Member for the RAND Center for Corporate Ethics and Governance, a member of the Committee for Economic Development's Subcommittee on Corporate Governance, and a member of The Conference Board Committee on Corporate Political Spending.